WO2010128071A1 - Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction - Google Patents
Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction Download PDFInfo
- Publication number
- WO2010128071A1 WO2010128071A1 PCT/EP2010/056081 EP2010056081W WO2010128071A1 WO 2010128071 A1 WO2010128071 A1 WO 2010128071A1 EP 2010056081 W EP2010056081 W EP 2010056081W WO 2010128071 A1 WO2010128071 A1 WO 2010128071A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medication
- disease
- fragments
- amino acid
- deaths
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5757—Vasoactive intestinal peptide [VIP] or related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention is in the field of clinical diagnostics. Particularly the present invention relates to the determi nation of the concentration of vasoactive hormones and their precursors and fragments thereof in a sample derived from a bodily fluid of a patient and the stratification of patients suffering from a disease related to endothelial function/dysfunction.
- vasoactive biomarkers and their precursors and fragments thereof stratify patients exhibiting a positive effect due to a specific medication.
- NT-proBNP for stratification of HF patients for medication was presented in the PRIMA-Study at the ACC Congress Orlando (29 lh March 2009).
- NT- proBNP measurements to identify patients with enhanced benefit from clopidogrel therapy was investigated by Tang et ai, but no NT-proBNP subgroup could be identified with an overproportionai benefit from clopidogrel therapy ⁇ Tang et al Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Obsen'ation (CREDO) substudy. American Heart Journal 2007; 153:36-41). Kropp et al. hypothesized that NT- proBNP could be used as a marker for the tolcrability and safety of antipsychotic drugs.
- NT-proBNP B-type natriuretic peptide
- ADM Alzheimer's et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Journal of the American College of Cardiology 2001:37:1781-7).
- patients were stratified according to peptide concentrations below and above median and a beneficial effect of carvediiol was not apparent until 300 days after treatment initiation, indicating that elevated plasma levels of the measured peptides may only predict a long-term benefit of the Beta-blocker carvedilol. Swedberg el al.
- the present invention is based on the surprising finding of the inventors that the levels of vasoactive hormones and their precursors and fragments thereof in samples of hodiiy fluids do not only correlate with a prognosis or diagnosis for a variety of diseases but can also be used to stratify patients into risk groups with respect to certain medications.
- the inventors have found that certain populations of patients exist for which the administration of particular medications has no effect on their outcome or even has an adverse (i.e. unfavourable) effect, e.g. a higher mortality as compared to patients that did not receive said medication.
- Such groups of patients can be identified with the methods of the present invention. This enables to avoid unnecessary or even harmful medications.
- one important object of the present methods of stratification is to avoid medication which is harmful to the patient.
- vasoactive hormones are molecules, e.g. peptides, causing constriction or dilation of blood vessels.
- vasoactive hormones in particular vasoactive peptides, arc unstable in bodily fluids like blood, urine or cerebrospinal fluid. Therefore, direct measurement of vasoactive peptides in bodily fluids is challenging.
- the precursors or precursor fragments of vasoactive peptides are more stable than the mature hormones, and their measurement can be used as a substitute or surrogate measurement for the mature vasoactive peptides. This has already been shown for a number of vasoactive peptides e.g. insulin and its stable precursor fragment C- pcptide (Melani et al. Identification of proinsulin and C -peptide in human serum bv a specific immunoassay.
- Endothelial dysfunction is a physiological dysfunction of normal biochemical processes carried out by the endothelium, the cells lining the inner surface of blood Endothelial dysfunction is characterized by an impaired vasodilation (imbalance beween relaxing and contracting factors) as well as changes in the proinflammatory state and prothrombic properties (Endemann and Schiffrin, Endothelial Dysfunction. Journal American Society of Nephrology 2004; 15: 1983-92), It is associated with cardiovascular diseases, such as hypertension, coronary artery disease, heart failure, peripheral artery disease, diabetes, and chronic renal failure. endothelial dysfunction is thought to be a key event in the development of atherosclerosis and predates clinically obvious vascular pathology by many years.
- Endothelial dysfunction has also been shown to be of prognostic significance in predicting vascular events including stroke and myocardial infarctions.
- endothelial dysfunction was shown to be implicated in inflammation and infection (Ste ⁇ vinket. Endothelial dysfunction and inflammation is there a link? Nephrology Dialysis and Transplantation 2001; 16: 1968-71), sepsis (Vallet. Bench-to-bedside review: Endothelial cell dysfunction in severe sepsis: a rote in organ dysfunction? Critical Care 2003:7:130-8; Peters et al. Molecular basis of endothelial dysfunction in sepsis. Cardiovascular Research 20()3;60:49-57) as well as COPD (Moro. Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology 2008;59:357 ⁇ 64).
- the present invention pertains to a method for the stratification of a subject having an acute or a chronic disease, wherein said disease effects endothelial function/dysfunction, comprising the steps of: taking a sample of bodily fluid from said subject; - determining in said sample of bodily fluid the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acids: stratifying said subjects into one of the following categories: (i) responder to a medication for treatment of said disease.
- the methods of the present invention comprise the provision of a system comprising the three categories (i), (ii) and (iii). In an even more preferred embodiment the methods of the present invention comprise the provision of at least two thresholds that are used in order to establish said system comprising and/or consisting of the three categories (i), (ii) and (iii).
- the term "responder" refers to a subject showing a favourable effect after having received a medication for treatment of a disease.
- non-responder in the context of the present invention refers to a subject showing no effect (neither a favourable nor an unfavourable effect) after having received a medication for treatment of a disease.
- categories (i) and (ii) arc pooled and distinguished from category (iii). i.e, the subjects are stratified into subjects showing an unfavourable effect and subjects not showing an unfavourable effect.
- the methods of the present invention comprise the provision of a system comprising and/or consisting of two categories, In an even more preferred embodiment this includes the provision of at least one threshold that is used to establish said two-categories- system.
- the ultimate object the two-categorics-system is the prevention of harm by medications.
- the invention also relates to a method for the stratification of a subject having an acute or a chronic disease, wherein said disease effects endothelial function/dysfunction, comprising the steps of: taking a sample of bodily fluid from said subject; - determining in said sample of bodily fluid the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues; stratifying said subjects into one of the following categories:
- the present invention also relates to a method for the stratification of a subject having an acute or a chronic disease, wherein said disease effects endothelial function/dysfunction, comprising the steps of: taking a sample of bodily fluid from said subject: determining in said sample of bodily fluid the concentration of a ⁇ asoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues: attributing the concentration of the vasoactive hormone or fragments thereof or precursors or fragments thereof in the sample to a risk of the subject of experiencing an unfavourable effect after receiving a particular medication.
- Subjects showing an unfavourable effect after having received said medication in the context of the present invention are subjects which are expected to experience an unfavourable effect upon administration of said medication.
- the vasoactive hormone is: (i) a peptide hormone selected from the group consisting of AdrenomedulH ⁇ (ADM),
- Atrial Natriuretic Peptide ANP
- Brain natriuretic peptide BNP
- C-type natriuretic peptide CNP
- Endothelin-1 Endothelin-2, Endothelin-3
- Arginin- Vasopressin AVP
- Dendr ⁇ aspis natriuretic peptide DNP
- Urodilarin Angiotensin II, Urocortin, Urocortin-2 (Stresscopin-related peptide), Urocortin-3 (Stresscopin), Urotensin-II, Urotensin II-rclated protein (URP), Neuropeptide Y (NPY), Vasoactive intestinal peptide (VlP), Calcitonin gene-related peptide 1 (CGRP 1) and Calcitonin gene-related peptide II (CGRP II), Insulin, Proenkephalin (PENK), Endokinin A, Dynorphin, Ghrelin, Relaxin
- a small peptide hormone selected from the group consisting of Bradykinin, ,
- Endokinin C Methionin-Enkephalin, Leucin-Enkephalin, or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues or
- a hormone selected from the group consisting of Serotonin. Prostaglandins and Thromboxane.
- the vasoactive hormone is:
- a peptide hormone selected from the group consisting of Adrenomedullin (ADM), Atria! Natriuretic Peptide (ANP), Brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP). Endothelin- 1 , Endothelin-2, Endothelin-3. Arginin- Vasopressin (AVP), Dendroaspis natriuretic peptide (DNP), L'rodilarin, Angiotensin IL Urocortin. Urocortin-2 (Strcsscopin-relatcd peptide), Urocortin-3
- a small peptide hormone selected from the group consisting of Bradykinin, , Ap el in, Neurotensin, Substance P, Neurokinin A (Substance K), Endokinin A/B, Endokinin C, Methionin-Enkephalin. Leucin-Enkephalin, or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues or
- peptide hormones in the context of the present invention are peptide hormones comprising 13 or less amino acid residues, in particular Bradykinin, , Apelin, Neurotensin, Substance P 5 Neurokinin A (Substance K), Mcthionin-Enkephalin and Lcucin-Enkephalin.
- Proenkcphalin is the precursor polypeptide of Methionin-Enkephalin and Leucin- Enkcphalin.
- the precursor fragment of the -vasoactive hormone ADM is Midregional pro-Adrenomedullin (MR ⁇ proADM) or a fragment thereof having a length of at least 12 amino acid residues.
- MR ⁇ proADM Midregional pro-Adrenomedullin
- the precursor fragment of the vasoactive hormone ANP is Midregionai pro-Atrial Natriuretic Peptide (MR-proANP) or a fragment thereof having a length of at least 12 amino acid residues.
- MR-proANP Midregionai pro-Atrial Natriuretic Peptide
- the precursor fragment of the vasoactive hormone ET-I is C -terminal pro-Endothelin-1 (CT-proET-1) or a fragment thereof having a length of at least 12 amino acid residues.
- the precursor fragment of the vasoactive hormone AVP is C-te ⁇ ninal pro- A VP (Copeptin) or a fragment thereof ha ⁇ ing a length of at least 12 amino acid residues.
- the disease may, e g., be selected from the group consisting of: chronic heart failure, shortness of breath (SOB), acute coronary syndrome, acute heart failure (AHF), arrhythmia, asthma exacerbation, bronchitis, chest pain, influenza, chronic obstructive pulmonary disease (COPD), pneumonia and pulmonary embolism, pulmonary artersal hypertension (PAH), post stroke condition, post myocardial infarct condition, diabetes type IL cancer, atherosclerosis, infections, inflammatory diseases, and post surgery condition.
- SOB shortness of breath
- AHF acute coronary syndrome
- AHF acute heart failure
- arrhythmia asthma exacerbation
- COPD chronic obstructive pulmonary disease
- COPD chronic obstructive pulmonary disease
- PAH pulmonary artersal hypertension
- post stroke condition post myocardial infarct condition
- diabetes type IL cancer atherosclerosis
- infections inflammatory diseases, and post surgery condition.
- the disease may, e.g., be selected from the group consisting of: chronic heart failure, shortness of breath (SOB), acute coronary syndrome, acute heart failure (AHF). arrhythmia, asthma exacerbation, bronchitis, chest pain, influenza, chronic obstructive pulmonary disease (COPD), pneumonia and pulmonary embolism, post stroke condition, post myocardial infarct condition, diabetes type II, cancer, atherosclerosis, infections, inflammatory diseases, and post surgery condition.
- SOB shortness of breath
- AHF acute heart failure
- arrhythmia asthma exacerbation
- COPD chronic obstructive pulmonary disease
- COPD chronic obstructive pulmonary disease
- pneumonia pulmonary embolism
- post stroke condition post myocardial infarct condition
- diabetes type II cancer
- cancer atherosclerosis
- infections inflammatory diseases
- inflammatory diseases and post surgery condition.
- the disease is selected from the group consisting of shortness of breath (SOB), acute coronary syndrome, acute heart failure (AHF), arrhythmia, asthma exacerbation, bronchitis, chest pain, influenza, chronic obstructive pulmonary disease (COPD), pneumonia and pulmonary embolism and pulmonary arterial hypertension (PAH).
- SOB shortness of breath
- AHF acute heart failure
- COPD chronic obstructive pulmonary disease
- PAH pulmonary embolism and pulmonary arterial hypertension
- the disease is selected from the group consisting of shortness of breath (SOB), acute coronary syndrome, acute heart failure (AHF), arrhythmia, asthma exacerbation, bronchitis, chest pain, influenza, chronic obstructive pulmonary disease (COPD), pneumonia and pulmonary embolism.
- SOB shortness of breath
- AHF acute heart failure
- COPD chronic obstructive pulmonary disease
- the disease is a post stroke condition, i.e. is related to subjects having suffered from ischemic or haemorrhagic stroke or transient ischemic attack (TIA).
- TIA transient ischemic attack
- Heart failure also termed congestive heart failure (CHF) is a cardiac condition that occurs when a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs.
- Chronic heart failure is a long term situation, usually with stable treated symptomatology.
- Acute heart failure is a term used to describe exacerbated or decompensated heart failure, referring to episodes in which a patient can be characterized as having a change in heart failure signs and symptoms resulting in a need for urgent therapy or hospitalization.
- SoB Shortness of breath
- heart diseases such as heart attack, congestive heart failure, and pulmonary diseases (incl. pneumonia).
- Acute coronary syndrome is an umbrella term used to cover any group of clinical symptoms compatible with acute myocardial ischemia.
- Acute myocardial ischemia is chest pain due to insufficient blood supply to the heart muscle that results from coronary artery disease (also called coronary heart disease).
- An acute coronary syndrome (ACS) is a set of signs and symptoms, usually a combination of chest pain and other features, interpreted as being the result of abruptly decreased blood flow to the heart (cardiac ischemia); the most common cause for this is the disruption of atherosclerotic plaque in an epicardial coronary artery.
- the subtypes of acute coronary syndrome include unstable angina (UA, not associated with heart muscle damage), and two forms of myocardial infarction (heart attack), in which heart muscle is damaged. These types are named according to the appearance of the electrocardiogram (ECG/EKG) as non-ST segment elevation myocardial infarction (NSTEMI) and ST segment elevation myocardial infarction (STEMI).
- Arrhythmia is a term for any of a large and heterogeneous group of conditions in which there is abnormal electrical activity in the heart.
- the heart beat may be too fast or too slow, and may be regular or irregular.
- Some arrhythmias are life-threatening medical emergencies that can result in cardiac arrest and sudden death. Others cause symptoms such as an abnormal awareness of heart beat (palpitations), and may be merely annoying. These palpitations have also been known to be caused by atrial/ventricular fibrillation, wire faults, and other technical or mechanical issues in cardiac pacemakers/defibrillators. Still others may not be associated with any symptoms at all. but may predispose the patient to potentially life threatening stroke or embolism.
- Asthma is a common chronic inflammatory disease of the airways characterized by variable and recurring symptoms, airflow obstruction, and bronchospasm. Symptoms include wheezing, cough, chest tightness, and shortness of breath. Some individuals will have stable asthma for weeks or months and then suddenly develop an episode of acute asthma. Different asthmatic individuals react differently to various factors. However, most individuals can develop severe exacerbation of asthma from several triggering agents.
- Bronchitis is inflammation of the mucous membranes of the bronchi, the airways that carry airflow from the trachea into the lungs. Bronchitis can be classified into two categories, acute and chronic, each of which has unique etiologies, pathologies, and therapies.
- Acute bronchitis is characterized by the development of a cough, with or without the production of sputum, mucus that is expectorated (coughed up) from the respiratory tract.
- Acute bronchitis often occurs during the course of an acute viral illness such as the common cold or influenza. Viruses cause about 90% of cases of acute bronchitis while bacteria account for less than
- Chronic bronchitis a type of chronic obstructive pulmonary disease, is characterized by the presence of a productive cough that lasts for 3 months or more per year for at least 2 U
- Cigarette smoking is the most common cause, followed by air pollution and occupational exposure to irritants, and cold air.
- COPD Chronic obstructive pulmonary disease
- emphysema a pair of two commonly co-existing diseases of the lungs in which the airways become nan-owed. This leads to a limitation of the flow of air to and from the lungs causing shortness of breath.
- COPD is caused by noxious particles or gas, most commonly from tobacco smoking, which triggers an abnormal inflammatory response in the lung.
- the Inflammatory response in the larger airways is known as chronic bronchitis, which is diagnosed clinically when people regularly cough up sputum.
- the inflammatory response causes destruction of the tissues of the lung, a process known as emphysema.
- the natural course of COPD is characterized by occasional sudden worsenings of symptoms called acute exacerbations, most of which are caused by infections or air pollution.
- Pneumonia is an abnormal inflammatory condition of the lung. It is often characterized as including inflammation of the parenchyma of the lung (that is. the alveoli) and abnormal alveolar filling with fluid (consolidation and exudation).
- the alveoli are microscopic air-filled sacs in the lungs responsible for gas exchange.
- Pneumonia can result from a variety of causes, including infection with bacteria, viruses, fungi, or parasites, and chemical or physical injury to the lungs. Its cause may also be officially described as idiopathic — that is, unknown — when infectious causes have been excluded. Typical symptoms associated with pneumonia include cough, chest pain, fever, and difficulty in breathing. Diagnostic tools include x-rays and examination of the sputum.
- Treatment depends on the cause of pneumonia: bacterial pneumonia is treated with antibiotics.
- Pneumonia is a common illness which occurs in all age groups, and is a leading cause of death among the elderly and people who are chronically and terminally ill. Additionally, it is the leading cause of death in children under five years old worldwide.
- Pulmonary embolism is a blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body through the bloodstream (embolism). Usually this is due to embolism of a thrombus (blood clot) from the deep veins in the legs, a process termed venous thromboembolism. A small proportion is due to the embolization of air. fat or amniotic fluid. The obstruction of the blood flow through the lungs and the resultant pressure on the right ventricle of the heart leads to the symptoms and signs of PE. The risk of PE is increased in various situations, such as cancer and prolonged bed rest. Symptoms of pulmonary embolism include difficulty breathing, chest pain on inspiration, and palpitations. Clinical signs include low blood oxygen saturation and cyanosis, rapid breathing, and a rapid heart rate. Severe cases of PE can lead to collapse, abnormally low blood pressure, and sudden death.
- Pulmonary arterial hypertension is a syndrome characterised by a progressive increase in pulmonary vascular resistance leading to right ventricular overload and eventually to right ventricular failure and premature death.
- Pulmonary Arterial Hypertension is defined as a sustained elevation of mean pulmonary arterial pressure to more than 25 raraHg at rest or to more than 30 mmHg while exercising, with a normal pulmonary wedge pressure ( ⁇ 15 mmHg). In most cases the earliest symptom is dyspnea on physical exertion. Other symptoms include syncope or near syncope, fatigue and peripheral oedema. Chest tightness and pain similar to angina may occur, particularly on physical exertion.
- Stroke is defined as an acute focal neurological deficit resulting from a cerebrovascular disease.
- the two main types of stroke are ischemic and hemorrhagic, accounting for approximately 85% and 15%, respectively.
- ischemic stroke occurs, the blood supply to the brain is interrupted, and brain cells are deprived of glucose and oxygen, Approximately 45% of ischemic strokes arc caused by small or large artery thrombus, 20% are embolic origin, and others have an unknown cause (Hickey 2003. The clinical practice of neurological and neurosurgical nursing (S' 1 ' eel.). Philadelphia: Lippincott, Williams & Wilkins).
- Transient ischemic attack (also known as "mini-stroke”) is a syndrome characterized by the sudden onset of discrete neurological symptoms that resolve completely within 24 hours. TIA may be reported by 0.5 - 8% of the elderly population (B ⁇ ts el al, 1997. Stroke 28(4): 768-73). A patient representing with a TIA is at high risk of subsequent adverse events. The 90-day risk of stroke has been repotted to be greater than 10%. with the highest risk occurring within the first 2 days (Jons ton ef al., 2003. Neurology- 60: 1429-34).
- MI Myocardial infarction
- AMI acute myocardial infarction
- a heart attack is the interruption of blood supply to part of the heart, causing some heart cells to die. This is most commonly due to occlusion (blockage) of a coronary artery following the rupture of a vulnerable atherosclerotic plaque, which is an unstable collection of lipids (fatty acids) and white blood cells (especially macrophages) in the wall of an artery.
- the resulting ischemia (restriction in blood supply) and oxygen shortage if left untreated for a sufficient period of time, can cause damage or death ⁇ infarction) of heart muscle tissue (myocardium).
- ST elevation MI STEM! or non-ST elevation MI (non-STEMI).
- Diabetes mellitus type 2 or type 2 diabetes is a disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency.
- Atherosclerosis also known as arteriosclerotic vascular disease or ASVD
- ASVD arteriosclerotic vascular disease
- the disease is a post myocardial infarct condition, i.e. subjects having suffered a myocardial infarction.
- the medication may, for example, be selected from the group consisting of anticoagulant, thrombolytic drugs, platelet aggregation inhibitor, ⁇ -blocker. anti-oxidant. lipid lowering substance, diuretic.
- ACE Angiotensin-Convcrting Enzyme
- calcium channel blocker calcium channel blocker
- endothelin-rcceptor antagonists phoshodicstcrase type 5 inhibitors
- prostacyclin derivatives soluble guanylate cyclisc activators
- hormone therapeutic agent NO substituent
- adenosine receptor blocker cardiac glycoside
- angiotensin-ll antagonist antidiabetic drug
- antiarrhythmic and antibiotic Particularly preferred medications are ACE inhibitors, diuretics and ⁇ -blockers.
- the medication may, for example, be selected from the group consisting of anticoagulant, thrombolytic drugs, platelet aggregation inhibitor, ⁇ -blocker, anti-oxidant, lipid lowering substance, diuretic.
- ACE Angiotensin-Converting Enzyme
- calcium channel blocker hormone therapeutic agent. NO substituent, adenosine receptor blocker, cardiac glycoside, angiotensin-Il antagonist, anti-diabetic drug, antiarrhythmic and antibiotic.
- Particularly preferred medications are ACE inhibitors, diuretics and ⁇ -blockers.
- the medication may also be a combination of two or more drugs such as ⁇ -blocker/calcium channel blocker ⁇ e.g. Belnif ⁇ , i.e. active ingredients: metoprolol 4 nifedipin), angiotcnsin-II antagonist en/diuretic (e.g. Blopress ⁇ - active ingredients: candesartan + hydrochlorothiazid).
- ⁇ -blocker/calcium channel blocker ⁇ e.g. Belnif ⁇ , i.e. active ingredients: metoprolol 4 nifedipin
- angiotcnsin-II antagonist en/diuretic e.g. Blopress ⁇ - active ingredients: candesartan + hydrochlorothiazid.
- the calcium channel blocker may for example be selected from the group consisting of dihydropyridine ⁇ e.g. Nicardipine), ph en ylalkyl amine (e.g. Verapamil). Benzodiazepine ⁇ e.g. Diltiazem), M ⁇ befradil and Fcndi ⁇ ne.
- the lipid lowering substance may for example be selected from the group consisting of statin (e.g. Lovastatin, Simvastatin* Pravastatin, Fluvastati ⁇ . Cerivastatin, Atorvastatin, Mevastatin, Pravastatin, Rosuvastatin), Fibrate (e.g. Bezafihrate, Fenofibratc. Elofibrate. Gemfibrozil), bile acid sequestrant ⁇ e.g. Cholestyramine. Colestipol) and nicotinic acid derivative (e.g. Acipimox, Xantinol nicotinate. Inositol nicotinate).
- statin e.g. Lovastatin, Simvastatin* Pravastatin, Fluvastati ⁇ . Cerivastatin, Atorvastatin, Mevastatin, Pravastatin, Rosuvastatin
- Fibrate e.g. Bezafihrate, Fenofibratc. Elofi
- the anti-oxidant may for example be selected from the group consisting of vitamin A, vitamin C, Oxypurionol. Superoxide dismutase. and Probucol,
- the ACE inhibitor may for example be selected from the group coconsisting of Captopril, Enalapril. Quanalapril. Peridoprii, Temocapril. Ramipril. Lisinopril.
- the hormone therapeutic agent may for example be selected from the group consisting of ⁇ Estradiol and Progesteron.
- the NO substituent may for example be selected from the group consisting of organic nitrates (e.g. nitroglycerine), sydnonimine and L-arginine.
- the anti-coagulant may for example be selected from the group consisting of a vitamin K antagonist (e.g. Phenprocoumon, Warfarin), a direct thrombin inhibitor (e.g. Lepirudin, Dcsirudin, Argatroban), Heparin.
- the thrombolytic drag may for example be selected from the group consisting of tissue plasminogen activator (tPA), rcteplase, tenectcplase, anistreplase, streptokinase, and urikinase.
- the platelet aggregation inhibitor may for example be selected from the group consisting of. Ticlopidin, Clopidogrel. Acctylsaiicylic Acid.
- the cardiac glycoside may for example be selected from the group consisting of Digoxin, Digitoxin, Deslanoside, Ouabain and Proscillaridin.
- the diuretic may for example be selected from the group consisting of a loop diuretic (e.g. Furosemidc), a benzothiadiazide diuretic (e.g. Metolazonc), a potassium sparing diuretic (e.g. Spironolactone) and an osmotic diuretic (e.g. Mannitol).
- a loop diuretic e.g. Furosemidc
- a benzothiadiazide diuretic e.g. Metolazonc
- a potassium sparing diuretic e.g. Spironolactone
- an osmotic diuretic e.g. Mannitol
- the angiotensin-]] antagonist may for example be selected from the group consisting of Candesartan. Eprosartan, lrbesartan. Telmisartan, Losartan, Valsartan and Olmesartan.
- the ⁇ -blocker may for example be selected from the group consisting of a ⁇ on-selelclive ⁇ - biocker ⁇ e.g. Nadolol. Penbuloloi). a ⁇ l -selective agent (e.g. Bisoprolol. Metoprolol), and a ⁇ l / ⁇ -adrenergic antagonist (e.g. Carvedilol, Celiprolol).
- a ⁇ on-selelclive ⁇ - biocker e.g. Nadolol. Penbuloloi
- a ⁇ l -selective agent e.g. Bisoprolol. Metoprolol
- a ⁇ l / ⁇ -adrenergic antagonist e.g. Carvedilol, Celiprolol
- the endothelin-receptor antagonists may for example be selected from the group consisting of a selective endothelin receptor type A antagonist (e.g. sitaxentan, ambrisentan, atrasentan, BQ- 123). a selective endothelin receptor B antagonist (e.g. sarafotoxin B). and a endothelin receptor A/B antagonist (e.g. bosentan, tezosentan).
- a selective endothelin receptor type A antagonist e.g. sitaxentan, ambrisentan, atrasentan, BQ- 123
- a selective endothelin receptor B antagonist e.g. sarafotoxin B
- a endothelin receptor A/B antagonist e.g. bosentan, tezosentan
- the phoshodiesterase type 5 inhibitors may for example be selected from the group consisting of sildenafil, sildenfil citrate, avanafil. lodenafil, mirodenafil, tadalafil, vardenafil, udenafil.
- the prostacyclin derivatives may for example be selected from the group consisting of cpoprostenol, treprostinil, iloprost, beraprost.
- the soluble guanylate cyclise activators may for example be selected from the group consisting of cinaciguat, riociguat.
- the antiarrhythmic may for example be selected from the group consisting of Chinidin, class 1 antiarrhythmics (e.g. Disopyramide, Lidocaine, Propafenone), class Il antiarrhythmics (e.g. Metoprolol), class III antiarrhythmics (e.g. Amiodarone, Sotalol), class IV antiarrhythmics (e.g. Verapamil, Diltiazem).
- the antibiotic may for example be selected from the group consisting of a Penicillin (e.g. Flucloxacillin, Amoxicillin, Ampicillin, Mezlocillin), a Cephalosporins (e.g. Ccfazolin, Cefuroxim. Cefotaxim. Cefaclor. Cefalexin). a ⁇ - Lactamase Inhibitor (e.g. Sulbactam. Tazobactam), a Tetracycline (e.g. Doxycyclin, Minocyclin, TetracycHn, Oxytetracyclin), an Aminoglycoside (e.g.
- a Penicillin e.g. Flucloxacillin, Amoxicillin, Ampicillin, Mezlocillin
- Cephalosporins e.g. Ccfazolin, Cefuroxim. Cefotaxim. Cefaclor. Cefalexin
- Gentamicin, Neomycin, Streptomycin a Makrolid-Antibiotic (e.g. Azithromycin, Clarithromycin, Erythromycin, Roxithromycin. Spiramycin, Clindamycin), a Lincosamide (e.g. Lincomycin), a Gyrase inhibitor (e.g. Ciprofloxacin, Ofloxacin, Norfloxacin), Sulfonamides, Trimethoprim, a GIycopeptide Antibiotic (e.g. Vancomycin), a polypeptide antibiotic (e.g. Colistin, Polymyxin), an Amphenicolc (e.g. Chloramphenicol).
- Makrolid-Antibiotic e.g. Azithromycin, Clarithromycin, Erythromycin, Roxithromycin.
- Spiramycin, Clindamycin a Lincosamide
- a Gyrase inhibitor e.g. Ciprofloxacin, Ofloxacin, Norfloxacin
- the anti-diabetic drug may for example be selected from the group consisting of insulins, alpha- glucosidase inhibitors. Biguanid derivatives (e.g. Metformin). Sulfonylurea derivatives (e.g. Glibenclamid, Tolbutamid) Pioglitazone, Rcpaglinid, Nateglinid. and Rosiglitazonemaleat.
- the disease is ischemic stroke
- the hormone precursor fragment to be determined is MR-proADM or a fragment thereof having a length of at least 12 amino acids and wherein the medication is statine.
- the patients arc preferably stratified into said categories using the following thresholds:
- the disease is ischemic stroke
- the hormone precursor fragment to be determined is MR- proADM or a fi-agment thereof having a length of at least 12 amino acids and wherein the medication is clopidogrel.
- the disease is ischemic stroke
- the hormone precursor fragment to be determined is CT-proAVP or a fragment thereof having a length of at least 12 amino acids and wherein the medication is acetylsalicylic acid.
- the disease is ischemic stroke
- the hormone precursor fragment to be determined is CT-proAVP or a fragment thereof having a length of at least 12 amino acids and wherein the medication is a diuretics.
- the patients are preferably stratified into said categories using the following thresholds:
- the disease is myocardial infarction
- the hormone precursor fragment to be determined is MR-proADM or a fragment thereof having a length of at least 1 2 amino acids and wherein the medication is a diuretic.
- the patients are preferably stratified into said categories using the following thresholds:
- the disease is post-myocardial infarction condition
- the hormone precursor fragment to be determined is CT-proAVP or a fragment thereof having a length of at least 12 amino acids and wherein the medication is an ACE inhibitor/adenosine receptor blocker (ARB).
- the patients are preferably stratified into said categories using the following thresholds: (i) responder to a medication for treatment of said disease: > 19 pmol/L CT- proAVP
- the unfavourable effect herein may e.g. be death or major adverse cardiac event (MACE).
- MACE major adverse cardiac event
- the outcome in terms of an unfavourable effect may be at a given time after entry of the patients into treatment, e.g. after admission in the emergency department.
- the outcome may be after several days, several weeks, several months or several years, e.g. 1 , 2, 3. 4, 5. 6, 7, 8. 9. 10, 1 1 or 12 weeks or 1. 2. 3, 4, 5, 6, 7. 8, 9 , 1 0, 11 or 12 months after admission.
- the bodily fluid is preferably selected from the group of blood, scrum, plasma, cerebrospinal fluid, urine, saliva, sputum, and pleural effusions. More preferably the sample is selected from whole blood, plasma or serum, most preferably the sample is plasma.
- the present invention also pertains to the use of an assay for the determination of the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues in a sample derived from a bodily fluid of a subject for the stratification of a subject having an acute or a chronic disease, into ei th er of th e categori GS :
- vasoactive hormone levels or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues can be employed.
- some subjects according to the present invention may also receive a combination of two or more medications. Also these subjects may be stratified in the context of the present invention.
- the invention also relates to the use of an antibody or a functional fragment thereof specific for a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues selected from the group of Adrenomedullin (ADM),
- ADM Adrenomedullin
- Atrial Natriuretic Peptide NBP
- Brain natriuretic peptide BNP
- CNP Endothelin-1 , Endothelin-2, Endothelin-3, Arginin- Vasopressin (AVP), Dendroaspis natriuretic peptide (DNP), Urodilatin, Angiotensin II, Urocortin, Urocortin-2 (Stresscopin- related peptide), Urocortin-3 (Stresscopin), Urotensin-ll, Urotensin Il-related protein (URP).
- AVP Arginin- Vasopressin
- DNP Dendroaspis natriuretic peptide
- Angiotensin II Urocortin
- Urocortin-2 Stresscopin- related peptide
- Urocortin-3 Stresscopin
- Urotensin-ll Urotensin Il-related protein
- Neuropeptide Y Neuropeptide Y
- VlP Vasoactive intestinal peptide
- CGRP I Calcitonin gene-related peptide II
- CGRP II Calcitonin gene-related peptide II
- Bradykinin Relaxin, Apelin
- Neurokinin A Substance K
- Endol ⁇ mn A Endokinin A/B
- Endokinin C Methionin-Enkephalin
- Lcucin-Enkephaiin in a method for the stratification of a subject having an acute or a chronic disease, into either of the categories:
- Suitable threshold levels for the stratification of subjects into different groups have to be determined for each particular combination of vasoactive hormone or fragments thereof or precursors or fragments thereof, medication and disease. This can e.g. be done by grouping a reference population of patients according to their level of vasoactive hormone into certain quantiles, e.g. tertiles, quartiles. quintilcs or even according to suitable percentiles. For each of the quantiles or groups above and below certain percentiles, hazard ratios can be calculated comparing the risk for an adverse outcome, i.e. an "unfavourable effect " , e.g. in terms of survival rate, between those patients who have received a certain medication and those who did not.
- a hazard ratio (HR) above 1 indicates a higher risk for an adverse outcome for the patients who have received a treatment than for patients who did not.
- a HR below 1 indicates beneficial effects of a certain treatment in the group of patients.
- a HR around i indicates no elevated risk but also no benefit from medication for the particular group of patients.
- At least two threshold levels of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acids have to be determined to stratify said subjects into one of the following categories:
- the present invention is not limited to those combinations of medications, diseases and vasoactive hormones or fragments thereof or precursors or fragments thereof demonstrated in the examples, but provides for a more general method.
- Determining (or measuring or detecting) the level of a vasoactive peptide hormone or fragment thereof or precursor or fragment thereof (also termed "marker peptide") herein may be performed using a detection method and/or a diagnostic assay as explained below.
- an “assay '1 or “diagnostic assay” can be of any type applied in the field of diagnostics. Such an assay may be based on the binding of an analyte to be detected to one or more capture probes with a certain affinity. Concerning the interaction between capture molecules and target molecules or molecules of interest, the affinity constant is preferably greater than 10 s M "1 .
- Capture molecules are molecules which ma; be used to bind target molecules or molecules of interest, i.e. analytes (i.e. in the context of the present invention the cardiovascular and/ or vasoactive peptide(s)). from a sample. Capture molecules must thus be shaped adequately, both spatially and in terms of surface features, such as surface charge, hydrophobicity, hydrophilicity, presence or absence of lewis donors and/or acceptors, to specifically bind the target molecules or molecules of interest.
- the binding may for instance be mediated by ionic, van-dcr-Waals, pi-pi, sigma-pi, hydrophobic or hydrogen bond interactions or a combination of two or more of the aforementioned interactions between the capture molecules and the target molecules or molecules of interest.
- capture molecules may for instance be selected from the group comprising a nucleic acid molecule, a carbohydrate molecule, a RNA molecule, a protein, an antibody, a peptide or a glycoprotein.
- the capture molecules arc antibodies, including fragments thereof with sufficient affinity to a target or molecule of interest, and including recombinant antibodies or recombinant antibody fragments, as well as chemically and/or biochemically modified derivatives of said antibodies or fragments derived from the variant chain with a length of at least 12 amino acids thereof.
- the preferred detection methods comprise immunoassays in various formats such as for instance radioimmunoassay (RIA), chemiluminescence- and fluorescence- immunoassays, Enzyme-linked immunoassays (ELISA), Luminex-based bead arrays, protein niicroarray assays, and rapid test formats such as for instance immuno chromatographic strip tests.
- RIA radioimmunoassay
- ELISA Enzyme-linked immunoassays
- Luminex-based bead arrays Luminex-based bead arrays
- protein niicroarray assays and rapid test formats such as for instance immuno chromatographic strip tests.
- the assays can be homogenous or heterogeneous assays, competitive and non-competitive assays.
- the assay is in the form of a sandwich assay, which is a non-competitive immunoassay, wherein the molecule to be detected and/or quantified is bound to a first antibody and to a second antibody.
- the first antibody may be bound to a solid phase, e.g. a bead, a surface of a well or other container, a chip or a strip
- the second antibody is an antibody which is labeled, e.g. with a dye, with a radioisotope, or a reactive or catalytically active moiety.
- the amount of labeled antibody bound to the analyte is then measured by an appropriate method.
- the general composition and procedures involved with “sandwich assays" are well-established and known to the skilled person. (The Immunoassay Handbook, Ed. David Wild, Elsevier LTD, Oxford; 3rd ⁇ d. (May 2005), ISBN- 13: 978-0080445267: Hultschig C et al, Cuir Opin Chem Biol. 2006 Feb;10(l):4-10. PMlD: 16376134), incoiporated herein by reference).
- the assay comprises two capture molecules, preferably antibodies which are both present as dispersions in a liquid reaction mixture, wherein a first labeling component is attached to the first capture molecule, wherein said first labeling component is part of a labeling system based on fluorescence- or chemilummescen.ee- quenching or amplification, and a second labeling component of said marking system is attached to the second capture molecule, so that upon binding of both capture molecules to the analyte a measurable signal is generated that allows for the detection of the formed sandwich complexes in the solution comprising the sample.
- said labeling system comprises rare earth cryptates or rare earth chelates in combination with a fluorescence dye or chemiiuminescence dye, in particular a dye of the cyanine type.
- fluorescence based assays comprise the use of dyes, which may for instance be selected from the group comprising FAJVI (5-or 6- carboxyfluorescein).
- VIC 5 NED Fluorescein, Fluoresceinisothiocyanate (FlTC), IRD- 700/800, Cyanine dyes, aucli as CY3.
- CY5. CY3.5. CY5.5, Cy7, Xanthen, 6-Carboxy- 2 " .4 * .7',4,7-hexachlorofluorcscein (HEX), TET, 6-Carboxy-4 ⁇ 5 ' -dichioro-2 ⁇ 7 " - diraethodyfluoresccin (JOE).
- TAMRA 6- Carboxy-X-rhodamine
- ROX 5-Carboxyrho
- chemi luminescence based assays comprise the use of dyes, based on the physical principles described for chemi luminescent materials in Kirk- Othmcr, Encyclopedia of chemical technology, 4" ed., executive editor, J. I. Kroschwitz; editor, M, Howe-Grant, John Wiley & Sons, 1993, vol. J 5, p. 518-562, incorporated herein by reference, including citations on pages 551 -562.
- Preferred chcmiluminescent dyes arc acridiniumcsters.
- the levels, i.e. the concentrations, of the one or more vasoactive hormones (or fragments thereof or precursors or fragments thereof) in the sample of the subject are used for the stratification of the subject into different risk groups for particular medications. For instance, concentrations of the vasoactive hormone (or fragments thereof or precursors or fragments thereof) above or in other cases below a certain threshold value is indicative for the risk of an unfavourable effect in the subject after having received said medication.
- Survival analysis (Cox regression and hazard ratios) and Kaplan -Meier estimators may be used for the assessment or prediction of the risk (e.g. morbidity) of a certain medication for a patient with a vasoactive hormone level (or fragments thereof or precursors or fragments thereof) e.g. above or below a cut off.
- risk e.g. morbidity
- vasoactive hormone level or fragments thereof or precursors or fragments thereof
- the amino acid sequence of the precursor peptide of Adrcnomed ⁇ llin (pre-pro- Adrenomedullin) is given in SEQ ID NO:1.
- Pro-Adrenomedu ⁇ lin relates to amino acid residues 22 to 185 of the sequence of pre-pro-Adrenomedullin.
- the amino acid sequence of pro-Adrenomedullin (pro- ADM) is given in SEQ ID NQ :2.
- the pro- ADM N-terminal 20 peptide (PAMP) relates to amino acid residues 22-41 of pre-proADM.
- the amino acid sequence of PAMP is given In SEQ ID NO:3.
- MR-pro-ADM relates to amino acid residues 45-92 of pre-pro-ADM.
- the amino acid sequence of MR-pro- ADM Is provided in SEQ ID NO:4.
- the amino acid sequence of mature Adrenomedullin (ADM) is given in SEQ ID NO:5.
- SEQ ID NO:1 amino acid sequence of pre-pro-ADM
- SEQ ID NO: 2 amino acid sequence of pro-ADM
- SEQ ID NO: 3 amino acid sequence of pro-ADM 3SF2G:
- SSQ ID NO: 4 amino acid sequence of MR-pro-ADM
- SEQ ID NO: 5 amino acid sequence of ADM
- ANP The amino acid sequence of the atrial natriuretic peptide (ANP) is given in SEQ ID NO:8.
- the sequence of the 153 amino acid pre-pro-AKP is shown in SEQ ID NO:6.
- SEQ ID NO:7 Upon cleavage of an N -terminal signal peptide (25 amino acids) and the two C -terminal amino acids ( 127/128) proANP (SEQ ID NO:7) is released.
- ANP comprises residues 99-126 from the C- terminus of the precursor prohormone pro- ANP. This prohormone is cleaved into the mature 28 amino acid peptide ANP.
- ANP also known as ANP ( 1-28) or ⁇ -ANP, and the amino terminal fragment ANP (1 -98) (NT-proANP, SEQ ID NO: 9).
- Mid -regional pro ANP is defined as NT-proANP or any fragments thereof comprising at least amino acid residues 53- 90 (SEQ ID NO: 10) of proANP.
- the C-terminal two arginine residues are not present in another allele of the gene encoding pre-pro- ANP, thus pre-pro-ANP may comprise only residues 1 to 153. This of course is also true for the respective fragments of pre-pro-ANP, particularly pro-ANP.
- SEQ ID NO: 6 amino acid sequence of pre-pro-ANP
- SEQ ID NO : 7 (amino acid sequence of pro-ANP) : 1 NPMYNAVSNA DLMDFKNLLD HLEEKMPLED EWPPQVLSE PNEEAGAALS 51 PLPEVPPWTG EVSPAQRDGG ALGRGPWDSS DRSALLKSKL RALLTAPRSL 101 RRSSCFGGRM DRIGAQ ⁇ GLG CNSFRY
- SEQ ID NO: 8 amino acid sequence of ANP: 1 SLRRSSCFGG RMDRIGAQSG LGCNSFRY
- SEQ ID NO: 9 amino acid sequence of NT-proANP:
- SEQ ID NO: 10 amino acid sequence of amino acids 53-90 of prOANP
- the sequence of the 164 amino acid precursor peptide of Vasopressin (pre-pro-Vasopressin) is given in SEQ ID NG: 1 1 .
- Pro-Vasopressin relates to the amino acid residues 29 to 164 of the sequence of pre-pro-Vasopressin.
- the amino acid sequence of pro- Vasopressin is given in SEQ ID NO: 12.
- Pro-Vasopressin is cleaved into mature Vasopressin, Ncurophysin II and C- terminal proVasopressin (CT-proAVP or Copeptin).
- Vasopressin relates to the amino acid residues 20 to 28 of pre-pro-Vasopressin.
- the amino acid sequence of Vasopressin is shown in SEQ ID NO: 13.
- Coeptin relates to amino acid residues 126 to 164 of pre-pro-Vasopressin.
- the amino acid sequence of Copeptin is provided in SEQ ID NO: 14.
- Neurophysin II comprises the amino acid residues 32 to 124 of pre-pro-Vasopressin and its sequence is shown in SEQ ID NO: 15.
- SEQ ID NO: 11 amino acid sequence of pre-pro-AVP:
- SEQ ID NO:12 amino acid sequence of pro-AVP
- SEQ ID NO: 14 (ammo acid sequence of CT-pre-proAVP or Copeptin) : 1 ASDRSNATQL DGPAGALLLR LVQLAGAPEP FEPAQPDAY
- SEQ ID NO: 15 (amino acid sequence of Neurophysin II) : 1 AMSDL ⁇ LRQC LPCGPGGKGR CFGPSICCAD ELGCFVGTAS ALRCQEENYL 51 PSPCQSGQKA CGSGGRCAAF GVCCND ⁇ SCV TEPECREGFH RRA
- the sequence of the 212 amino acid precursor peptide of Endothelin-1 (prc-pro-Endothelin- 1 ) is given in SEQ ID NO: 16.
- Pro-ET-1 relates to the amino acid residues 18 to 212 of the sequence of pre-pro-ET- 1.
- the amino acid sequence of pro-ET- 1 is given in SEQ ID NO: 17.
- Pro-ET-1 is cleaved into mature ET-I . big-ET-1 and C-te ⁇ ninal proET-1 (CT-proET-1).
- ET-I relates to the amino acid residues 53 to 73 of pre-pro-ET-1.
- the amino acid sequence of ET-I is shown in SEQ ID NO: 18.
- CT-proET-1 relates to amino acid residues 168 to 212 of pre-pro- ET-1.
- the amino acid sequence of CT -pro ET-I is provided in SEQ ID NO; 19.
- Big-ET-1 comprises the amino acid residues 53 to 90 of pre-pro-ET-1 and its sequence is shown in SEQ ID NO:20.
- SEQ ID NO: 16 (amino acid sequence of pre-pro-ET-1) • . 1 MDYLLMIFSL LFVACQGAPE TAVLGAELSA VGENGGEKPT PSPPWRLRRS 51 KRCSCSSLMD KECVYFCHLD IIWVNTPEHV VPYGLGSPRS KRALENLLPT Ii
- SEQ ID NO: 17 amino acid sequence of pro-ET-1 :
- SEQ ID NO:19 amino acid sequence of CT-pro-ET-1 :
- SEQ ID NO:20 amino acid sequence of Big-ET-1 :
- the sequence of the 134 amino acid precursor peptide of brain natriuretic peptide is given in SEQ ID NO:21 .
- Pro-BNP relates to amino acid residues 27 to 134 of pro- pro-BNP.
- the sequence of pro-BNP is shown in SEQ ID NO:22.
- Pro-BNP is cleaved into N- tcrminal pro-BNP (NT-pro-BNP) and mature BNP, NT-pro-BNP comprises the amino acid residues 27 to 102 and its sequence is shown in SEQ SD NO.23.
- the SEQ ID NO:24 shows the sequence of BNP comprising the amino acid residues 103 to 134 of the pre-pro-BNP peptide.
- SEQ ID NO:21 amino acid sequence of pre-pro-BNP:
- SEQ ID NG:22 amino acid sequence of pro-BNP:
- SEQ ID NO: 24 amino acid sequence of BNP
- Figures 1 to 8 illustrate the survival rate for patients suffering from shortness of breath (SOB), acute coronary syndrome, acute heart failure (AHF). arrhythmia, asthma exacerbation, bronchitis, chest pain, influenza, chronic obstructive pulmonary disease (COPD), pneumonia and pulmonary embolism from the "Biomarkers in the Assessment of Congestive Heart failure study " " (“BACH “” ).
- Fig. 5 Marker CT ⁇ proET-l and medicament Beta-Block or; solid line means no medication, dashed line means medication;
- FIGs 9 to 13 illustrate the survival rate for patients suffering from ischemic stroke, hemorrhagic stroke or transient ischemic attack from the "Copeptin to guide disease severity and Management. Osmostatus and Stress "" (“COSMOS " ).
- Fig. 9 Marker CT-proAVP and Medicament Diuretic; solid line means no medication, dashed line means medication:
- n 20 with medication (dcaths-0);
- n !
- Figures 14 to 21 illustrate the survival rate for patients suffering from myocardial infarction from the "Leicester Acute Myocardial Infarction Peptide Study " ("'LAMP *' ).
- Figures 22 to 34 illustrate the rate of major cardiac events for patients suffering from acute myocardial infarction from "LAMP-Study " .
- Fig. 23 Marker MR-proANP and Medicament Calcium Channel Blocker; solid line means no medication, dashed line means medication;
- MR-proANP and MR-proADM were detected using novel fully automated sandwich immunoassay systems on the B.R.A.H.M.S KRYPTOR (B.R.A.H.M.S AG. Hcnnigsdorf/ Berlin, Germany) (Canthel et al. 2009, Clin Biochem 42:725-8).
- This random access analyzer employs the sensitive Time Resolved Amplified Cryptatc Emission (TRACE) technology, based on a non-radioactive-transfer between 2 fluorophores. europium cryptate and XL665. Both automated assays are based essentially on the sandwich chemiluminescence assays which are described in detail elsewhere ⁇ Morgenthaler et al. 2004.
- MR-proANP detection 14 ⁇ l of patients serum were incubated for 14 min.
- the measuring range was 0-10000 pmol/L, the limit of detection 2.1 pmol/L. and the limit of quantitation 4.5 pmol/L.
- CT-proAVP Copeptin
- CT -pro ET- 1 levels were measured with a chemiluminescence sandwich immunoassay with a lower detection limit of 0.4 pmol/L (Papassotiriau et al. 2006. Clin Chem 52: 1144- 51).
- CT-proET-1 values followed a Gaussian distribution with a mean (SD) of 44.3 (10.6) pmol/L and a range of 10.5-77.4 pmol/L.
- SD mean
- CV intra assay imprecision
- BNP was measured with Triage two-site immunoassay reagents (Biosite, San Diego, CA) formatted for Becknian Coulter instrumentation (Brea, CA). Performance in the laboratory included a limit of quantitation of 5.0 ng/L, within run imprecision (CV) of 1.5% and total imprecision (CV) of 3.0%.
- NTproBNP was measured by electrochemiluminescence on the ElecSys 2010 analyzer (Roche Diagnostics, Indianapolis, IN). Performance in the laboratory included a limit of quantitation of 10.0 ng/L, within run imprecision (CV) of 1 .5% and total imprecision (CV) of 3.0%.
- the present invention is based on patients and samples from the following clinical studies:
- the study was set at the emergency and neurological and neurosurgical clinic of the University Hospital of Basel. All consecutive patients who arc admitted to the emergency department with an ischemic or hemorrhagic stroke or transient ischemic attack (TIA) according to the World Health Organization criteria with symptom onset within the last 3 days were included into the study. Patients without an informed consent were excluded.
- TIA transient ischemic attack
- hyponatremia severe hypothyroidism, glucocorticoid insufficiency, neoplasm, HlV infection
- smoking history packet-years
- status packet per day
- time from onset of symptoms to admission e
- Place of residence i.e.
- volume status incJuding skin turgor, jugular venous distension, auscultation, if available flow sheet of fluid intake and loss), body temperature; in neurosurgical patients intracerebral pressure if performed within the routine clinical management.
- Clinical symptoms of hyponatremia will be evaluated on admission and in case of sodium imbalance in neurological patients. In patients undergoing intracranial surgery we will evaluate clinical symptoms daily. Specifically we will monitor the presence of headache, anorexia, nausea, vomiting, muscle cramps and aches, seizures, confusion, apathetic or lethargic development.
- Routine/Standard laboratory tests routine blood sampling including: hematocrit, blood urea nitrogen, bicarbonate, total protein, albumin, uric acid serum and urine electrolytes, urine and serum osmolality, creatinine, lipids, TSH, fT4, T3, and basal Cortisol. All blood sampling will be done before any food intake, or smoking, if feasible. Alternatively, influencing factors will be monitored.
- Imaging Computer tomography or MRI of the ⁇ eurocranium (Tl, T2, diffusion-weighted image sequence, with or without contrast), if indicated magnetic resonance angiography or conventional cerebral angiography. We will record the time-points of contrast agent application.
- Stroke patients will also be classified on the basis of the vascular territory of the ischemic lesion as follows: total anterior circulation syndrome (TACS), partial anterior circulation syndrome (PACS), lacunar circulation syndrome (LACS), posterior circulation syndrome (POCS). j) Further investigations: Stroke patients will have neurosonography, echocardiography, standard 12-leaf electrocardiography and 24 -hour electrocardiography and then will be classified by etiology of strokes according to Trial of Org 10172 in acute Treatment (TOAST) stroke subtype classification, which differs between large artery atherosclerosis, cardioembolism, small-artery occlusion, other etiology, and undetermined etiology.
- TOAST acute Treatment
- Step 1 All eligible patients in the emergency department or the neurological ward will be included into the study,
- Step 3 During hospitalization we Clinical items including weight, blood pressure, pulse rate, volume status and body temperature will be assessed by chart review until discharge. Fluid treatment and drugs.
- hyponatremia i.e. headache, nausea, vomiting, muscle cramps and aches, anorexia, impaired consciousness, seizure.
- Routinely performed laboratory tests chcmogramm, plasma glucose, serum osmolality, urine osmolality, sodium in urine, hematocrit
- chcmogramm plasma glucose, serum osmolality, urine osmolality, sodium in urine, hematocrit
- Step 4 In all patients, on day 5 of the hospitalization, a clinical examination with NIHSS, Barthel Index and Ranking Scale will be performed (CoMn et al 1988.
- the Barthel ADL The Barthel ADL
- Step 5 The future place of residence ⁇ i.e. dependent vs. independent living) will be assessed. Step 5. In patients with ischemic stroke a telephone follow-up regarding morbidity and mortality (as assessed by the Barthel Index and Ranking Scale) will be obtained after 3 months. An unfavorable outcome will be defined as a Barthel Index ⁇ 85 or modified
- Acute myocardial infarction was diagnosed if a patient had a plasma creatinine kinase-MB elevation greater than twice normal or a cardiac Troponin I level >0.1 ng/ml with at least 1 of the following: chest pain lasting >20min or diagnostic serial electrocardiographic changes consisting of new pathological Q waves or ST-segment and T-wave changes.
- Acute myocardial infarction was subcategorized into ST-segment elevation myocardial infarction (STEMI) or non-ST-segnient myocardial infarction (NSTEMI).
- the study complied with the Declaration of Helsinki and was approved by the local ethics committee. Written informed consent was obtained from all patients. Exclusion criteria were known malignancy, or surgery in the previous month.
- the estimated glomerular filtration rate (eGFR) was calculated from the simplified formula derived from the MDRD (Modification of Diet in Renal Disease) study, recently validated in patients with HF ⁇ Smilde et al. 2006. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Ciculation 114: 1572-80).
- Plasma samples were calculated from the simplified formula derived from the MDRD (Modification of Diet in Renal Disease) study, recently validated in patients with HF ⁇ Smilde et al. 2006. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Ciculation 114: 1572-80).
- EDTA ethylendiaminetetraacetic acid
- Transthoracic echocardiography was performed in patients using Sonos 5500 instrument (Philips Medical Systems, Rcigate, UK).
- Left ventricular ejection fraction was calculated using the biplane method of discs formula (Schiller et al. 1989. Recommendations for quantitation of the left ventricule by two-dimensional echocardiography. American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2: 358-67).
- cardiologists reviewed ail medical records pertaining to the patient and independently classified the diagnosis as dyspnea due to congestive heart failure, pneumonia or due to other underlying disease. Both cardiologists were blinded to each other, the investigational markers, as well as the emergency physician ' s preliminary diagnosis. They did have access to the emergency department case report forms that included chest radiographic data, radionuclide angiography, echocardiography, medical history, catheterization data and the hospital course for patients who were admitted to the hospital. In the event of diagnostic disagreement among the cardiology reviewers they were asked to meet to come to a common conclusion.
- MR-proANP and MR-proADM were detected using novel fully automated sandwich immunoassay systems on the B.R.A.H.M.S KRYPTOR (B.R.A.H.M.S AG, Hcnnigsdorf/
- This random access analyzer employs the sensitive Time Resolved Amplified Cryptate Emission (1 " RACE) technology, based on a non-radioactive-transfcr between 2 fluorophores. europium cryptate and XL665. Both automated assays are based essentially on the sandwich chemilummescence assays which are described in detail elsewhere (Morgenthaler et al. 2004 Clin C hem 50:234-6;
- MR-proANP detection 14 ⁇ l of patients scrum were incubated for 14 min.
- the measuring range was 0-10000 pmol/L, the limit of detection 2.1 pmol/L. and the limit of quantitation 4.5 pmol/L.
- Table 1 lists the results for the patients from the BACH study (patients suffering from shortness of breath (SOB), acute coronary syndrome, acute heart failure (AHF), arrhythmia, asthma exacerbation, bronchitis, chest pain, influenza, chronic obstructive pulmonary disease (COPD), pneumonia and/or pulmonary embolism.).
- SOB shortness of breath
- AHF acute heart failure
- arrhythmia asthma exacerbation
- COPD chronic obstructive pulmonary disease
- COPD chronic obstructive pulmonary disease
- Table 1 lists the results for the patients from the BACH study (patients suffering from shortness of breath (SOB), acute coronary syndrome, acute heart failure (AHF), arrhythmia, asthma exacerbation, bronchitis, chest pain, influenza, chronic obstructive pulmonary disease (COPD), pneumonia and/or pulmonary embolism.).
- vasoactive hormones the administration of e.g. calcium-channel blockers, diuretics and statins
- Table 2 lists the results for the patients from the COSMOS study (patients having suffered from ischemic or haemorrhagic stroke or TIA).
- the administration of statins, anti-coagulants and plavix has an unfavourable effect, while at higher levels the administration of these drugs has a positive effect.
- the administration of acetyisaiicylic acid, thrombolytic drugs, diuretics and steroids has an unfavourable effect, while at lower levels the administration of these drugs has a positive effect.
- Table 3 lists the results for the patients from the LAMP study (patients having suffered a myocardial infarction) in respect to death as the unfavourable effect (outcome).
- the administration of the medication except for thrombolytic drugs when the hormone is proANP
- the administration of the drugs has an unfavourable effect, while at higher levels the administration of the drugs has a positive effect
- Table 4 lists the results for the patients from the LAMP study (patients having suffered a myocardial infarction) in respect to MACE as the unfavourable effect (outcome).
- the administration of the medication except for thrombolytic drugs when the hormone is pro AN P
- the administration of the drugs has an unfavourable effect, while at higher levels the administration of the drugs has a positive effect.
- Beta-Blocker BNP 1 .1 15.1 0.5-26.4 0.6 26.4-748 0.7 748-1070
- Steroid BNP 1 ⁇ 0.1 0.5-26.4 1 .5 26.4-748 1 .5 748-1070
- ACE-lnhibitor CT-ET-1 0.7 >100 11.8-54 0.5 54-157 0 4 157-752
- Beta-Blocker CT-ET-1 0.7 >100 6.9-67 0.7 67-182 0.4 182-709
- Blocker NT-proBNP 0.6 5.8 3-280 0.6 280-7080 0.2 7080-112000
- MR-proADM values in nmol/L MR-proANP values in pmol/L
- CT-proAVP values in pmoI/L BNP values in pg/mL
- CT-proET-1 values in pmol/L CT-proET-1 values in pmol/L
- NT-proBNP values in pg/mL * Quintiles 1 to 4 are pooled
- Thrombolysis MR-proADM 1 6 ⁇ 0 1 0 05-0 53 1 0.53-1 0 4 1 0-8 1
- Anti-Coagulant MR-proANP 1 2 >100 20-71 2 0 6 71 2-235 0 7 235-954
- MR-proADM values in nmol/L MR-proANP values in pmol/L
- CT-proAVP values in pmo!/L CT-proET-1 values in pmol/L * Guintiles 1 to 4 are pooled
- Medication Biomarkar overall Biomarker Biomarker Biomarker in Marker- in Marker- in Marker- patient Quintile 1 Qu ⁇ ntlle 2-4 Quintiie 5 Qua ⁇ tile 1 Quant ⁇ le 2-4 Quantile 5 group
- MR-proADM values in nmoi/L MR-proANP values in pmo!/L r CT-proAVP values in pmol/L, CT-proET-1 values in pmol/L, NT-proBNP values m pg/mL
- ACE Inhibitor CT-proET-1 04 >100 37-654 07 654-136 02 136-468
- MR-proADSVt values in nmoi/L MR-proANP values in pmoi/L
- CT-proAVP values in pmol/L CT-proET-1 values in pmoi/L
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES10717643.0T ES2643033T3 (en) | 2009-05-05 | 2010-05-05 | Stratification based on vasoactive hormone in patients suffering from diseases related to endothelial function / dysfunction |
EP10717643.0A EP2427764B1 (en) | 2009-05-05 | 2010-05-05 | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
DK10717643.0T DK2427764T3 (en) | 2009-05-05 | 2010-05-05 | VASOACTIVE HORMON-BASED STRATIFICATION OF PATIENTS SUFFERING OF DISEASES RELATED TO ENDOTELIAL FUNCTION / DYSFUNCTION |
CN201080020210.7A CN102428368B (en) | 2009-05-05 | 2010-05-05 | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
US13/318,488 US9229013B2 (en) | 2009-05-05 | 2010-05-05 | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
JP2012509026A JP5753159B2 (en) | 2009-05-05 | 2010-05-05 | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function / dysfunction |
HK12108726.0A HK1168146A1 (en) | 2009-05-05 | 2012-09-06 | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function dysfunction |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09159472.1 | 2009-05-05 | ||
EP09159472 | 2009-05-05 | ||
EP09163269.5 | 2009-06-19 | ||
EP09163269 | 2009-06-19 | ||
EP09016143.1 | 2009-12-30 | ||
EP09016143 | 2009-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010128071A1 true WO2010128071A1 (en) | 2010-11-11 |
Family
ID=42224880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/056081 WO2010128071A1 (en) | 2009-05-05 | 2010-05-05 | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
Country Status (8)
Country | Link |
---|---|
US (1) | US9229013B2 (en) |
EP (1) | EP2427764B1 (en) |
JP (1) | JP5753159B2 (en) |
CN (1) | CN102428368B (en) |
DK (1) | DK2427764T3 (en) |
ES (1) | ES2643033T3 (en) |
HK (1) | HK1168146A1 (en) |
WO (1) | WO2010128071A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013132088A1 (en) * | 2012-03-08 | 2013-09-12 | Sphingotec Gmbh | A method for predicting the risk of getting a cardiovascular event in a female subject |
WO2013159872A1 (en) * | 2012-04-26 | 2013-10-31 | B.R.A.H.M.S. Gmbh | Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope |
WO2015049243A1 (en) * | 2013-10-01 | 2015-04-09 | Sphingotec Gmbh | A method for predicting the risk of getting a major adverse cardiac event |
US20180348235A1 (en) * | 2015-11-27 | 2018-12-06 | B.R.A.H.M.S Gmbh | MR-proADM as marker for the extracellular volume status of a subject |
WO2019053115A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | Pro-adm as a therapy monitoring marker for critcally ill patients |
WO2019053118A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | Proadrenomedullin as a marker for abnormal platelet levels |
CN109799338A (en) * | 2019-01-14 | 2019-05-24 | 湖南达道生物工程有限公司 | A kind of test paper and its application suitable for peripheral blood immunochromatography quantitative detection |
EP4023218A1 (en) * | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
US11592450B2 (en) | 2017-08-04 | 2023-02-28 | B.R.A.H.M.S Gmbh | Diagnosis and risk stratification of fungal infections |
US12000845B2 (en) | 2017-09-13 | 2024-06-04 | B.R.A.H.M.S Gmbh | Method for discharging a patient from an intensive care unit |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10316583A1 (en) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Determination of a mid-regional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, as well as immunoassays for carrying out such a determination |
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
ES2550004T3 (en) | 2006-04-04 | 2015-11-03 | Singulex, Inc. | High sensitivity system and troponin analysis methods |
DE102006053442A1 (en) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnosis and risk stratification of infections and chronic diseases of the respiratory and lungs by means of proVasopressin, in particular copeptin or neurophysin II |
AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
RU2671578C2 (en) * | 2012-10-02 | 2018-11-02 | Сфинготек Гмбх | Method for predicting risk of getting cancer or diagnosing cancer in female subject |
CN104937419B (en) * | 2013-01-08 | 2018-08-10 | 斯弗因高泰克有限公司 | The method predicted the cancered risk of subject or diagnose cancer |
WO2015013167A1 (en) * | 2013-07-25 | 2015-01-29 | Novartis Ag | Disulfide cyclic polypeptides for the treatment of heart failure |
CN105612173A (en) * | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | Cyclic APELIN derivatives for the treatment of heart failure |
US20160166651A1 (en) * | 2014-04-03 | 2016-06-16 | The Regents Of The University Of California | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure |
CA2889826A1 (en) * | 2014-06-20 | 2015-12-20 | Emmanuel E. Egom | Methods of treating pulmonary hypertention by administration of natriuretic peptide receptor c signaling pathway activators |
ES2807960T3 (en) * | 2016-04-08 | 2021-02-24 | Lunginnov | Method for diagnosing postoperative lung infections in patients who underwent surgery |
MX2019000003A (en) * | 2016-07-08 | 2019-08-29 | Sphingotec Gmbh | Adrenomedullin for assessing congestion in a subject with acute heart failure. |
MX2019014441A (en) * | 2017-05-30 | 2020-02-10 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction. |
CN107335051A (en) * | 2017-08-18 | 2017-11-10 | 温州医科大学附属第医院 | A kind of pharmaceutical composition for protecting chronic heart failure renal function |
CN111065922A (en) * | 2017-09-13 | 2020-04-24 | B.R.A.H.M.S有限公司 | Pro-adrenomedullin as an indicator for renal replacement therapy in critically ill patients |
CN109283341A (en) * | 2018-10-17 | 2019-01-29 | 北京市心肺血管疾病研究所 | The biomarker of the PCI Postoperative determination of one group of prediction myocardial infarction patient |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006060835A1 (en) * | 2006-12-22 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnosis and risk stratification of acute coronary syndrome using CT-proET-1 in combination with NT-proBNP |
DE102007010834A1 (en) * | 2007-03-03 | 2008-09-04 | Brahms Aktiengesellschaft | Method for in-vitro diagnosis or risk classification or outcome prognosis of heart failure for New york heart association patient, involves utilizing determination of marker proatrial natriuretic peptide |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
MXPA03004105A (en) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Making a prognosis in cases of cardiac disease using a combination of markers. |
GB2403533A (en) * | 2003-06-30 | 2005-01-05 | Orion Corp | Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof |
DE102006034142A1 (en) * | 2006-07-24 | 2008-01-31 | B.R.A.H.M.S. Aktiengesellschaft | Method for controlling the therapy of heart failure patients by the in vitro determination of threshold levels of vasoactive peptides |
US20080050749A1 (en) * | 2006-08-17 | 2008-02-28 | Ildiko Amann-Zalan | Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents |
EP2084543B1 (en) * | 2006-10-26 | 2017-10-18 | B.R.A.H.M.S GmbH | Risk stratification for acute coronary syndrome by means of fragments/partial peptides of provasopressin, especially copeptin or neurophysin ii |
DE102006060112A1 (en) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnosis and risk stratification using the new marker CT-proADM |
DE102007021443A1 (en) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnosis and risk stratification using NT-proET-1 |
EP2020603A1 (en) * | 2007-08-03 | 2009-02-04 | BRAHMS Aktiengesellschaft | Method for risk stratification in stable coronary artery disease |
-
2010
- 2010-05-05 WO PCT/EP2010/056081 patent/WO2010128071A1/en active Application Filing
- 2010-05-05 US US13/318,488 patent/US9229013B2/en active Active
- 2010-05-05 CN CN201080020210.7A patent/CN102428368B/en active Active
- 2010-05-05 EP EP10717643.0A patent/EP2427764B1/en active Active
- 2010-05-05 JP JP2012509026A patent/JP5753159B2/en active Active
- 2010-05-05 ES ES10717643.0T patent/ES2643033T3/en active Active
- 2010-05-05 DK DK10717643.0T patent/DK2427764T3/en active
-
2012
- 2012-09-06 HK HK12108726.0A patent/HK1168146A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006060835A1 (en) * | 2006-12-22 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnosis and risk stratification of acute coronary syndrome using CT-proET-1 in combination with NT-proBNP |
DE102007010834A1 (en) * | 2007-03-03 | 2008-09-04 | Brahms Aktiengesellschaft | Method for in-vitro diagnosis or risk classification or outcome prognosis of heart failure for New york heart association patient, involves utilizing determination of marker proatrial natriuretic peptide |
Non-Patent Citations (53)
Title |
---|
"Moro. Endothelial dyfunction in chronic obstructive pulmonary disease", ANGIOLAGY, vol. 59, 2008, pages 357 - 64 |
ADAMS ET AL.: "Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST)", NEUROLOGY, vol. 53, 1999, pages 126 - 31 |
BECK-DA-SILVA ET AL.: "BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure", CONGESTIVE HEART FAILURE, vol. 11, 2005, pages 248 - 53 |
BONITA; BEAGLEHOLE: "Modification of Ranking Scale: Recovery of motor function after stroke", STROKE, vol. 19, 1988, pages 1497 - 1500 |
BOTS ET AL., STROKE, vol. 28, no. (4), 1997, pages 768 - 73 |
CARUHEL ET AL., CLIN BIOCHEIN, vol. 42, 2009, pages 725 - 8 |
CARUHEL ET AL., CLIN BIOCHEM, vol. 42, 2009, pages 725 - 8 |
COLLIN ET AL.: "The Barthel ADL Index: a reliability study", INTERNATIONAL DISABILITY STUDY, vol. 10, 1988, pages 61 - 3 |
DAVIS ET AL.: "Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure", CIRCULATION, vol. 113, 2006, pages 977 - 85 |
ENDEMANN; SCHIFFRIN, ENDOTHELIAL DYSFUNCTION. JOURNAL AMERICAN SOCIETY OF NEPHROLOGY, vol. 15, 2004, pages 1983 - 92 |
ERNST ET AL., PROENKEPHALIN A, pages 119 - 159 |
ERNST ET AL.: "a stable neurotensin precursor fragment identified in human circulation. Peptides", PRONEUROTENSIN, vol. 27, 2006, pages 1787 - 93, XP025067439, DOI: doi:10.1016/j.peptides.2006.01.021 |
ERNST ET AL.: "Detection of a stable N-terminal protachykinin A immunoreactivity in human plasma and cerebrospinal fluid", PEPLIDES, vol. 29, 2008, pages 1201 - 6, XP022704821, DOI: doi:10.1016/j.peptides.2008.02.006 |
GEGENHUBER ET AL., CLIN CHEM, vol. 52, 2006, pages 827 - 31 |
GEGENHUBER ET AL: "Comparative Evaluation of B-Type Natriuretic Peptide, Mid-Regional Pro-A-type Natriuretic Peptide, Mid-Regional Pro-Adrenomedullin, and Copeptin to Predict 1-Year Mortality in Patients With Acute Destabilized Heart Failure", JOURNAL OF CARDIAL FAILURE, CHURCHILL LIVINGSTONE, NAPERVILLE, IL, US LNKD- DOI:10.1016/J.CARDFAIL.2006.09.004, vol. 13, no. 1, 3 March 2007 (2007-03-03), pages 42 - 49, XP005910325, ISSN: 1071-9164 * |
GOLDSTEIN ET AL.: "Charlson Index comorbidity adjustment for ischemic stroke outcome studies", STROKE, vol. 35, 2004, pages 1941 - 5 |
HULTSCHIG C ET AL., CURR OPIN CHEM BIOL., vol. 10, no. 1, February 2006 (2006-02-01), pages 4 - 10 |
JONSTON ET AL., NEUROLOGY, vol. 60, 2003, pages 1429 - 34 |
KHAN ET AL., J AM COLL CARDIOL, vol. 49, 2007, pages 1525 - 32 |
KHAN ET AL., J AM COLL CARDIOL, vol. 51, 2008, pages 1857 - 64 |
KHAN ET AL., JAM COLL CARDIOF, vol. 49, 2007, pages 1525 - 32 |
KHAN ET AL., JAM COLL CARDIOL, vol. 51, 2008, pages 1857 - 64 |
KHAN SOHAIL Q ET AL: "C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction Leicester acute myocardial infarction peptide (LAMP) study", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US LNKD- DOI:10.1161/CIRCULATIONAHA.106.685503, vol. 115, no. 16, 1 April 2007 (2007-04-01), pages 2103 - 2110, XP002491227, ISSN: 0009-7322 * |
KJAER, VIDENSKAH OG PRAKSIS, vol. 162, 2000, pages 5910 - 3 |
MANT ET AL.: "Identification and guided treatment of ventricular dysfuncion in general practice using blood B-type natriuretic peptide", BRITISH JOURNAL OF GENERAL PRACTICE, vol. 58, 2008, pages 393 - 9 |
MELANI ET AL.: "Identification of proinsulin and C-peptide in human serum by a specific immunoassay", PNAS, vol. 67, 1970, pages 148 - 55 |
MORGENTHALER ET AL., CLIN CHEM, vol. 50, 2004, pages 234 - 6 |
MORGENTHALER ET AL., CLIN CHEM, vol. 51, 2005, pages 1823 - 9 |
MORGENTHALER ET AL., CLIN CHEM, vol. 52, 2006, pages 112 - 9 |
MORGENTHALER ET AL.: "Assay for the measurement of copeptin, astable peptide derived from the precursor of vasopressin", CLINICAL CHEMISTRY, vol. 52, 2006, pages 112 - 9 |
MORGENTHALER ET AL.: "Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma", CLINICAL CHEMISTRY, vol. 50, 2004, pages 234 - 6 |
MORGENTHALER ET AL.: "Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay", CLINICAL CHEMISTRY, vol. 51, 2005, pages 1823 - 9, XP002510789, DOI: doi:10.1373/CLINCHEM.2005.051110 |
MORGENTHALER, CLIN CHEM, vol. 51, 2005, pages 1823 - 9 |
PAPASSOTIRIOU ET AL., CLIN CHEM, vol. 52, 2006, pages 1144 - 51 |
PAPASSOTIRIOU ET AL.: "lmmunoluminometric assay the measurement of the C-terminal endothelin-1 precursor fragment in human plasma", CLINICAL CHEMISTRY, vol. 52, 2006, pages 1144 - 51 |
PEPTIDES, vol. 27, 2006, pages 1835 - 40 |
PETERS ET AL.: "Molecular basis of endothelial dysfunction in sepsis", CARDIOVACULAR RESEARCH, vol. 60, 2003, pages 49 - 57 |
RICHARDS ET AL.: "Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular Australia-New Zealand Heart Failure Group", CIRCULATION, vol. 99, 1999, pages 786 - 92 |
RICHARDS ET AL.: "Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin - prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 37, 2001, pages 1781 - 7 |
ROTHWELL ET AL.: "A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack", LANCET, vol. 366, 2005, pages 29 - 36, XP025276683, DOI: doi:10.1016/S0140-6736(05)66702-5 |
SCHILLER ET AL.: "Recommendations for quantitation of the left ventricule by two-dimensional echocardiography. American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms", J AM SOC ECHOCARDIOGR, vol. 2, 1989, pages 358 - 67, XP002331754 |
SMILDE ET AL.: "Drawbacks and prognostic value (of formulas estimating renal function in patients with chronic heart fàilure and systolic dysfunction", CICULATION, vol. 114, 2006, pages 1572 - 80 |
STENVINKEL: "Endothelial dysfinction and inflammation is there a link?", NEPHROLOLOGY DIALYSIS AND TRANSPLANTATION, vol. 16, 2001, pages 1968 - 71 |
STRUCK ET AL.: "Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients", PEPTIDES, vol. 25, 2005, pages 2500 - 4, XP025378571, DOI: doi:10.1016/j.peptides.2005.04.019 |
STRUCK ET AL.: "Identification of an adrenomedullin precursor fragment in plasma of sepsis patients", PEPTIDES, vol. 25, 2004, pages 1369 - 72, XP004551479, DOI: doi:10.1016/j.peptides.2004.06.019 |
STRUCK ET AL.: "Proteolytic processing pattern of the endotlielin-1 precursor in vivo", PEPTIDES, vol. 26, 2005, pages 2482 - 6 |
SWEDBERG ET AL.: "Hormones regulating cardiovascular fímction in patients with severe congestive heart failure and their relation to mortality CONSENSUS Trial study group", CIRCULATION, vol. 82, 1990, pages 1730 - 6 |
TANG ET AL.: "Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy", AMERICAN HEART JOURNAL, vol. 153, 2007, pages 36 - 41, XP005750595, DOI: doi:10.1016/j.ahj.2006.10.011 |
VALLET.: "Bench-to-bedside review: Endothelial cell dysfunction in severe sepsis: a role in organ dysfunction?", CRITICAL CARE, vol. 7, 2003, pages 130 - 8 |
VAN HAEHLING ET AL., J AM COLL CARDIOL. IN PRESS, 2009 |
VAN- HAEHLING ET AL., J AM COLL CARDIOL. IN PRESS, 2009 |
VON HAEHLING ET AL: "Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US LNKD- DOI:10.1016/J.JACC.2007.08.012, vol. 50, no. 20, 29 October 2007 (2007-10-29), pages 1973 - 1980, XP022332007, ISSN: 0735-1097 * |
WASYWICH ET AL.: "Changes in tissue-Doppler echocardiographic assessment of left ventricular filling during NT-proBNP guided heart failure treatment titration: a pilot study", HEART LUNG AND CIRCULATION, vol. 18, 2009, pages 38 - 44, XP025928418, DOI: doi:10.1016/j.hlc.2008.07.002 |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2652304C2 (en) * | 2012-03-08 | 2018-04-25 | Сфинготек Гмбх | Method for predicting risk of getting cardiovascular event in female subject |
WO2013132088A1 (en) * | 2012-03-08 | 2013-09-12 | Sphingotec Gmbh | A method for predicting the risk of getting a cardiovascular event in a female subject |
WO2013159872A1 (en) * | 2012-04-26 | 2013-10-31 | B.R.A.H.M.S. Gmbh | Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope |
RU2613885C2 (en) * | 2012-04-26 | 2017-03-21 | Б.Р.А.Х.М.С. Гмбх | Biomarkers for diagnosis, prediction, assessment and stratification of fainting therapy |
RU2727022C2 (en) * | 2013-10-01 | 2020-07-17 | Сфинготек Гмбх | Method for prediction of risk of severe adverse cardiac events |
WO2015049243A1 (en) * | 2013-10-01 | 2015-04-09 | Sphingotec Gmbh | A method for predicting the risk of getting a major adverse cardiac event |
US20180348235A1 (en) * | 2015-11-27 | 2018-12-06 | B.R.A.H.M.S Gmbh | MR-proADM as marker for the extracellular volume status of a subject |
US11592450B2 (en) | 2017-08-04 | 2023-02-28 | B.R.A.H.M.S Gmbh | Diagnosis and risk stratification of fungal infections |
EP3971572A1 (en) * | 2017-09-13 | 2022-03-23 | B.R.A.H.M.S GmbH | Proadrenomedullin as a marker for abnormal platelet levels |
EP3971573A1 (en) * | 2017-09-13 | 2022-03-23 | B.R.A.H.M.S GmbH | Proadrenomedullin as a marker for abnormal platelet levels |
WO2019053118A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | Proadrenomedullin as a marker for abnormal platelet levels |
US11327082B2 (en) | 2017-09-13 | 2022-05-10 | B.R.A.H.M.S Gmbh | Proadrenomedullin as a marker for abnormal platelet levels |
WO2019053115A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | Pro-adm as a therapy monitoring marker for critcally ill patients |
US12000845B2 (en) | 2017-09-13 | 2024-06-04 | B.R.A.H.M.S Gmbh | Method for discharging a patient from an intensive care unit |
CN109799338A (en) * | 2019-01-14 | 2019-05-24 | 湖南达道生物工程有限公司 | A kind of test paper and its application suitable for peripheral blood immunochromatography quantitative detection |
CN109799338B (en) * | 2019-01-14 | 2022-02-11 | 湖南达道生物工程有限公司 | Test paper suitable for peripheral blood immunochromatographic quantitative detection and application thereof |
EP4023218A1 (en) * | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
WO2022117893A3 (en) * | 2020-12-02 | 2022-07-14 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
Also Published As
Publication number | Publication date |
---|---|
EP2427764A1 (en) | 2012-03-14 |
US20120142120A1 (en) | 2012-06-07 |
CN102428368A (en) | 2012-04-25 |
HK1168146A1 (en) | 2012-12-21 |
JP2012526271A (en) | 2012-10-25 |
CN102428368B (en) | 2015-04-22 |
JP5753159B2 (en) | 2015-07-22 |
DK2427764T3 (en) | 2017-09-11 |
US9229013B2 (en) | 2016-01-05 |
ES2643033T3 (en) | 2017-11-21 |
EP2427764B1 (en) | 2017-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9229013B2 (en) | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction | |
EP2356450B1 (en) | Prognosis and risk assessment in stroke patients by determining the level of marker peptides | |
Krauser et al. | Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy | |
Bayés‐Genís et al. | N‐terminal probrain natriuretic peptide (NT‐proBNP) in the emergency diagnosis and in‐hospital monitoring of patients with dyspnoea and ventricular dysfunction | |
EP2353011B1 (en) | Biomarker for the prediction of first adverse events | |
JP6062532B2 (en) | Biomarkers for syncope diagnosis, prognosis, assessment, and treatment stratification | |
US20180052179A1 (en) | Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin | |
EP2737320B1 (en) | MID-REGIONAL PRO-ATRIAL NATRIURETIC PEPTIDE (MR-proANP) FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION WITH AN ONSET OF LESS THAN 48 HOURS AGO | |
Wu et al. | N-terminal pro-brain natriuretic peptide is a biomarker of congestive heart failure and predictive of 30-day untoward clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention | |
Shaikh et al. | Diagnostic significance of NT-proBNP estimation in patients with acute dyspnea | |
Hess et al. | N-Terminales-proBNP (NT-proBNP)—Ein Indikator für kardiale Dysfunktion: A study in patients presenting with suspected cardiac disorders | |
Tokavanich et al. | Circulating growth differentiation factor‐15 as a novel biomarker in heart transplant | |
坂井健一郎 | Brain natriuretic peptide as a predictor of cardioembolism in acute ischemic stroke patients: brain natriuretic peptide stroke prospective study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080020210.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10717643 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2199/MUMNP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012509026 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2010717643 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010717643 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13318488 Country of ref document: US |